THC and CBD: timing mattered for the double act

In an Irish experiment, CBD proved no universal peacemaker: the result depended on its company and timing. Researchers worked with blood-derived immune cells from 61 people – 31 with multiple sclerosis and 30 without it. In cells from people with the condition, consistent suppression of signaling through the NLRP3 inflammatory mechanism was seen only with tetrahydrocannabinol (THC) and cannabidiol (CBD) together, added before the first triggering signal. When the compounds were added before the second activation stage, no anti-inflammatory effect was detected in those cells. Frontiers in Immunology accepted the study on 2 November; its abstract is available, while the final formatted version is still being prepared. The experiment did not assess how people felt – it examined only their cells’ responses.